FI3893924T3 - Ihmisen komplementtitekijän C2B vasta-aineita sekä niiden käyttötapoja - Google Patents
Ihmisen komplementtitekijän C2B vasta-aineita sekä niiden käyttötapoja Download PDFInfo
- Publication number
- FI3893924T3 FI3893924T3 FIEP19832737.1T FI19832737T FI3893924T3 FI 3893924 T3 FI3893924 T3 FI 3893924T3 FI 19832737 T FI19832737 T FI 19832737T FI 3893924 T3 FI3893924 T3 FI 3893924T3
- Authority
- FI
- Finland
- Prior art keywords
- monoclonal antibody
- antigen
- binding fragment
- heavy chain
- vector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Devices For Post-Treatments, Processing, Supply, Discharge, And Other Processes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779102P | 2018-12-13 | 2018-12-13 | |
| PCT/IB2019/060802 WO2020121282A1 (en) | 2018-12-13 | 2019-12-13 | Antibodies to human complement factor c2b and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3893924T3 true FI3893924T3 (fi) | 2024-10-04 |
Family
ID=69143627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19832737.1T FI3893924T3 (fi) | 2018-12-13 | 2019-12-13 | Ihmisen komplementtitekijän C2B vasta-aineita sekä niiden käyttötapoja |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US11161900B2 (enExample) |
| EP (2) | EP3893924B1 (enExample) |
| JP (3) | JP7110491B2 (enExample) |
| KR (2) | KR102774146B1 (enExample) |
| CN (2) | CN119371526A (enExample) |
| AU (3) | AU2019397614B2 (enExample) |
| BR (1) | BR112021011107A2 (enExample) |
| CA (1) | CA3119655A1 (enExample) |
| DK (1) | DK3893924T3 (enExample) |
| EA (1) | EA202191658A1 (enExample) |
| ES (1) | ES2991894T3 (enExample) |
| FI (1) | FI3893924T3 (enExample) |
| HU (1) | HUE068993T2 (enExample) |
| IL (2) | IL283916B2 (enExample) |
| LT (1) | LT3893924T (enExample) |
| MX (2) | MX2021006864A (enExample) |
| PL (1) | PL3893924T3 (enExample) |
| PT (1) | PT3893924T (enExample) |
| SG (1) | SG11202105195PA (enExample) |
| WO (1) | WO2020121282A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11161900B2 (en) * | 2018-12-13 | 2021-11-02 | Argenx Bvba | Antibodies that specifically bind to human complement factor C2b |
| GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
| GB202407051D0 (en) | 2024-05-17 | 2024-07-03 | argenx BV | Methods of treating osteoarthritis pain |
| WO2025257157A1 (en) | 2024-06-10 | 2025-12-18 | argenx BV | Treatment or prevention of ischemia reperfusion injury in organ tranplantation |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2329010T3 (es) | 2000-03-23 | 2009-11-20 | Genentech, Inc. | Inhibidores anti-c2/c2a de la activacion del complemento. |
| US8501705B2 (en) | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| US8163881B2 (en) | 2005-05-31 | 2012-04-24 | The Board Of Regents Of The University Of Texas System | Immunoglobulin molecules with improved characteristics |
| EP2010214A4 (en) | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
| AU2007257692B2 (en) | 2006-06-12 | 2013-11-14 | Aptevo Research And Development Llc | Single-chain multivalent binding proteins with effector function |
| PT2698166E (pt) | 2006-10-10 | 2016-01-27 | Regenesance B V | Inibição do complemento para regeneração nervosa aprimorada |
| SG190626A1 (en) | 2008-05-05 | 2013-06-28 | Novimmune Sa | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |
| AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010056399A1 (en) | 2008-11-17 | 2010-05-20 | Incode Biopharmaceutics, Inc. | Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors |
| CN103249432A (zh) * | 2010-06-22 | 2013-08-14 | 科罗拉多大学董事会,法人团体 | 补体成分3的C3d片段的抗体 |
| EP2998320B1 (en) * | 2011-04-19 | 2018-07-18 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
| KR101641057B1 (ko) * | 2011-05-04 | 2016-07-20 | 오메로스 코포레이션 | Masp-2 의존적 보체 활성화를 억제하는 조성물 |
| EP2753636B1 (en) | 2011-09-07 | 2019-10-23 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with improved pharmacokinetic properties |
| WO2014096958A1 (en) | 2012-11-02 | 2014-06-26 | Academisch Medisch Centrum | Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders |
| US8945562B2 (en) * | 2012-11-02 | 2015-02-03 | True North Therapeutics, Inc. | Anti-complement C1s antibodies |
| EP2996722A4 (en) | 2013-05-15 | 2017-01-11 | Annexon, Inc. | Methods of treatment for guillain-barre syndrome |
| LT2999714T (lt) | 2013-05-23 | 2020-07-10 | Broteio Pharma B.V. | Surišančios molekulės, kurios suriša žmogaus komplemento faktorių c2 ir jų panaudojimas |
| CA2859114A1 (en) | 2013-08-29 | 2015-02-28 | International Automotive Components Group North America, Inc. | Formed articles comprising carbon and natural fibers, methods of manufacture and use thereof |
| LT3052192T (lt) | 2013-10-02 | 2020-12-10 | Medimmune, Llc | Neutralizuojantys antikūnai prieš gripą a ir jų naudojimas |
| CN105683219B (zh) * | 2013-10-17 | 2020-07-14 | 奥默罗斯公司 | 用于治疗与masp-2依赖性补体活化有关的病况的方法 |
| BR112016013148B1 (pt) | 2013-12-12 | 2024-02-27 | Alnylam Pharmaceuticals, Inc | ÁCIDO RIBONUCLEICO DE FITA DUPLA (dsRNA) PARA INIBIÇÃO DA EXPRESSÃO DO FATOR B DO COMPLEMENTO (CFB) EM UMA CÉLULA, COMPOSIÇÃO FARMACÊUTICA PARA INIBIÇÃO DA EXPRESSÃO DE UM GENE DO FATOR B DO COMPLEMENTO, SEU USO, E MÉTODO IN VITRO DE INIBIÇÃO DA EXPRESSÃO DO FATOR B DO COMPLEMENTO (CFB) EM UMA CÉLULA |
| LT3215527T (lt) | 2014-11-05 | 2025-04-10 | Annexon, Inc. | Humanizuoti antikūnai prieš komplemento faktorių c1q ir jų panaudojimas |
| WO2017087800A1 (en) * | 2015-11-19 | 2017-05-26 | Abbvie Stemcentrx Llc | Novel anti-emr2 antibodies and methods of use |
| WO2017091719A1 (en) | 2015-11-24 | 2017-06-01 | Annexon, Inc. | Anti-complement factor c1q fab fragments and uses thereof |
| MA53248A (fr) * | 2016-01-25 | 2022-02-16 | Takeda Pharmaceuticals Co | Anticorps anti-c5 à commutation ph améliorée |
| SG10201911561SA (en) | 2016-01-27 | 2020-02-27 | CSL Behring Lengnau AG | Recombinant igg fc multimers |
| WO2017196960A1 (en) | 2016-05-10 | 2017-11-16 | Annexon, Inc. | Anti-complement factor c4/c4b antibodies and uses thereof |
| WO2018107109A1 (en) * | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Novel anti-kremen2 antibodies and methods of use |
| CA3055781A1 (en) | 2017-03-14 | 2018-09-20 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases and disorders |
| JP2020517242A (ja) * | 2017-04-21 | 2020-06-18 | スターテン・バイオテクノロジー・ベー・フェー | 抗ＡｐｏＣ３抗体およびその使用方法 |
| CA3078971A1 (en) | 2017-11-01 | 2019-05-09 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
| US11161900B2 (en) * | 2018-12-13 | 2021-11-02 | Argenx Bvba | Antibodies that specifically bind to human complement factor C2b |
| GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
-
2019
- 2019-12-13 US US16/714,264 patent/US11161900B2/en active Active
- 2019-12-13 EA EA202191658A patent/EA202191658A1/ru unknown
- 2019-12-13 MX MX2021006864A patent/MX2021006864A/es unknown
- 2019-12-13 HU HUE19832737A patent/HUE068993T2/hu unknown
- 2019-12-13 BR BR112021011107A patent/BR112021011107A2/pt unknown
- 2019-12-13 CN CN202411410387.8A patent/CN119371526A/zh active Pending
- 2019-12-13 AU AU2019397614A patent/AU2019397614B2/en active Active
- 2019-12-13 PT PT198327371T patent/PT3893924T/pt unknown
- 2019-12-13 WO PCT/IB2019/060802 patent/WO2020121282A1/en not_active Ceased
- 2019-12-13 KR KR1020217021353A patent/KR102774146B1/ko active Active
- 2019-12-13 IL IL283916A patent/IL283916B2/en unknown
- 2019-12-13 FI FIEP19832737.1T patent/FI3893924T3/fi active
- 2019-12-13 SG SG11202105195PA patent/SG11202105195PA/en unknown
- 2019-12-13 ES ES19832737T patent/ES2991894T3/es active Active
- 2019-12-13 DK DK19832737.1T patent/DK3893924T3/da active
- 2019-12-13 IL IL319975A patent/IL319975A/en unknown
- 2019-12-13 PL PL19832737.1T patent/PL3893924T3/pl unknown
- 2019-12-13 KR KR1020257005663A patent/KR20250030005A/ko active Pending
- 2019-12-13 LT LTEPPCT/IB2019/060802T patent/LT3893924T/lt unknown
- 2019-12-13 CN CN201980082826.8A patent/CN113260375B/zh active Active
- 2019-12-13 EP EP19832737.1A patent/EP3893924B1/en active Active
- 2019-12-13 JP JP2021533300A patent/JP7110491B2/ja active Active
- 2019-12-13 EP EP24164880.7A patent/EP4375297A3/en active Pending
- 2019-12-13 CA CA3119655A patent/CA3119655A1/en active Pending
-
2021
- 2021-06-10 MX MX2025010337A patent/MX2025010337A/es unknown
- 2021-10-01 US US17/491,656 patent/US11591386B2/en active Active
-
2022
- 2022-01-10 US US17/572,518 patent/US11708403B2/en active Active
- 2022-07-20 JP JP2022115252A patent/JP7611191B2/ja active Active
- 2022-12-15 AU AU2022287637A patent/AU2022287637B2/en active Active
-
2023
- 2023-06-07 US US18/330,903 patent/US20240002484A1/en active Pending
-
2024
- 2024-08-01 JP JP2024125608A patent/JP2024160274A/ja active Pending
-
2025
- 2025-10-17 AU AU2025252632A patent/AU2025252632A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7345578B2 (ja) | 新規抗ｐｄ－ｌ１抗体 | |
| FI3893924T3 (fi) | Ihmisen komplementtitekijän C2B vasta-aineita sekä niiden käyttötapoja | |
| JP6576969B2 (ja) | 抗ｃｄ３抗体およびその使用方法 | |
| US11773177B2 (en) | Variant antibodies that bind OX40 | |
| WO2018137576A1 (zh) | 抗pd-1单克隆抗体及其制备方法和应用 | |
| US20080206229A1 (en) | Modified Antibodies Recognizing Receptor Trimers or Higher Multimers | |
| US20070003556A1 (en) | Modified antibodies against cd22 and utilization thereof | |
| JP6421371B2 (ja) | トランスポーターに対する抗体およびその用途 | |
| TW201741340A (zh) | Cd47抗體及使用其之方法 | |
| TW201731874A (zh) | Bcma及cd3雙特異性t細胞嚙合抗體構築體 | |
| TW201706307A (zh) | Ｃｄ７０及ｃｄ３抗體構築體 | |
| CA3004830A1 (en) | Composition and methods for anti-tnfr2 antibodies | |
| TW201716441A (zh) | Ｅｇｆｒｖｉｉｉ及ｃｄ３抗體構築體 | |
| CN111320693B (zh) | 抗EphA4抗体 | |
| CA2597717A1 (en) | Antibodies against cxcr4 and methods of use thereof | |
| TWI788698B (zh) | 抗ｐｄ-ｌ１抗體及其應用 | |
| EA039946B1 (ru) | Антитела-антагонисты к интерферону альфа и интерферону омега | |
| JP2022160479A5 (enExample) | ||
| US20250243272A1 (en) | Epitope of regulatory t cell surface antigen, and antibody specifically binding thereto | |
| CN110305214A (zh) | 新型抗cd47抗体 | |
| AU2024266887A1 (en) | Epitope of regulatory T cell surface antigen and antibody specifically binding thereto | |
| JP2024026820A (ja) | 医薬組成物、その製造方法及び用途 | |
| KR20150134319A (ko) | 인간화 항 hmgb1 항체 또는 그의 항원 결합성 단편 | |
| JP2021075517A (ja) | 抗ｔｉｇｉｔ抗体および使用方法 | |
| WO2022212429A1 (en) | Anti-viral compositions for rift valley fever virus infections and methods of using same |